APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Targeted Peptide Weight Loss Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global GLP-1 Targeted Peptide Weight Loss Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173995420327 December 2025198 pages

Choose your research edition.

Industry ResearchGLP-1 Targeted Peptide Weight Loss Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Targeted Peptide Weight Loss Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global GLP-1 Targeted Peptide Weight Loss Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Targeted Peptide Weight Loss Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Targeted Peptide Weight Loss Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Targeted Peptide Weight Loss Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Targeted Peptide Weight Loss Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Company

Chugai Pharmaceutical

Benemae Pharmaceutical

Qilu Pharmaceutical

Jiuyuan Gene Engineering

Huadong Medicine

Zealand Pharma

The General Hospital Corp

Sanofi-Aventis

QuiaPEG Pharmaceuticals Ab

Orbis Biosciences

Novo Nordisk

Nano Precision Medical

Nanexa AB

Lexaria Bioscience

iX Biopharma

Intarcia Therapeutics

HIKMA PHARMS

Eli Lilly

Baxter Pharmaceutical

Astra Zeneca

Amylin Pharmaceuticals

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type

Oral

Injection

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application

Hospital

Clinic

Others

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Targeted Peptide Weight Loss Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends Table 2. GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers Table 3. GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges Table 4. GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints Table 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Manufacturers Table 9. Global GLP-1 Targeted Peptide Weight Loss Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global GLP-1 Targeted Peptide Weight Loss Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global GLP-1 Targeted Peptide Weight Loss Drugs Manufacturers, Product Type & Application Table 13. Global GLP-1 Targeted Peptide Weight Loss Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Targeted Peptide Weight Loss Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2021-2026) Table 22. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2027-2032) Table 23. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2021-2026) Table 27. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2021-2026) Table 35. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2027-2032) Table 36. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2021-2026) Table 40. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2027-2032) Table 41. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2021-2026) Table 44. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2021-2026) Table 62. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2027-2032) Table 63. Chugai Pharmaceutical Company Information Table 64. Chugai Pharmaceutical Business Overview Table 65. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 67. Chugai Pharmaceutical Recent Development Table 68. Benemae Pharmaceutical Company Information Table 69. Benemae Pharmaceutical Business Overview Table 70. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 72. Benemae Pharmaceutical Recent Development Table 73. Qilu Pharmaceutical Company Information Table 74. Qilu Pharmaceutical Business Overview Table 75. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 77. Qilu Pharmaceutical Recent Development Table 78. Jiuyuan Gene Engineering Company Information Table 79. Jiuyuan Gene Engineering Business Overview Table 80. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 82. Jiuyuan Gene Engineering Recent Development Table 83. Huadong Medicine Company Information Table 84. Huadong Medicine Business Overview Table 85. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 87. Huadong Medicine Recent Development Table 88. Zealand Pharma Company Information Table 89. Zealand Pharma Business Overview Table 90. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 92. Zealand Pharma Recent Development Table 93. The General Hospital Corp Company Information Table 94. The General Hospital Corp Business Overview Table 95. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 97. The General Hospital Corp Recent Development Table 98. Sanofi-Aventis Company Information Table 99. Sanofi-Aventis Business Overview Table 100. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 102. Sanofi-Aventis Recent Development Table 103. QuiaPEG Pharmaceuticals Ab Company Information Table 104. QuiaPEG Pharmaceuticals Ab Business Overview Table 105. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 107. QuiaPEG Pharmaceuticals Ab Recent Development Table 108. Orbis Biosciences Company Information Table 109. Orbis Biosciences Business Overview Table 110. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 112. Orbis Biosciences Recent Development Table 113. Novo Nordisk Company Information Table 114. Novo Nordisk Business Overview Table 115. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 117. Novo Nordisk Recent Development Table 118. Nano Precision Medical Company Information Table 119. Nano Precision Medical Business Overview Table 120. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 122. Nano Precision Medical Recent Development Table 123. Nanexa AB Company Information Table 124. Nanexa AB Business Overview Table 125. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 127. Nanexa AB Recent Development Table 128. Lexaria Bioscience Company Information Table 129. Lexaria Bioscience Business Overview Table 130. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 132. Lexaria Bioscience Recent Development Table 133. iX Biopharma Company Information Table 134. iX Biopharma Business Overview Table 135. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 137. iX Biopharma Recent Development Table 138. Intarcia Therapeutics Company Information Table 139. Intarcia Therapeutics Business Overview Table 140. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 142. Intarcia Therapeutics Recent Development Table 143. HIKMA PHARMS Company Information Table 144. HIKMA PHARMS Business Overview Table 145. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 147. HIKMA PHARMS Recent Development Table 148. Eli Lilly Company Information Table 149. Eli Lilly Business Overview Table 150. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 152. Eli Lilly Recent Development Table 153. Baxter Pharmaceutical Company Information Table 154. Baxter Pharmaceutical Business Overview Table 155. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 157. Baxter Pharmaceutical Recent Development Table 158. Astra Zeneca Company Information Table 159. Astra Zeneca Business Overview Table 160. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 162. Astra Zeneca Recent Development Table 163. Amylin Pharmaceuticals Company Information Table 164. Amylin Pharmaceuticals Business Overview Table 165. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 167. Amylin Pharmaceuticals Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. GLP-1 Targeted Peptide Weight Loss Drugs Distributors List Table 171. GLP-1 Targeted Peptide Weight Loss Drugs Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. GLP-1 Targeted Peptide Weight Loss Drugs Product Image Figure 2. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (2021-2032) & (K Units) Figure 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2021-2032) Figure 13. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2021-2032) Figure 22. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 39. China GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chugai Pharmaceutical
  • Benemae Pharmaceutical
  • Qilu Pharmaceutical
  • Jiuyuan Gene Engineering
  • Huadong Medicine
  • Zealand Pharma
  • The General Hospital Corp
  • Sanofi-Aventis
  • QuiaPEG Pharmaceuticals Ab
  • Orbis Biosciences
  • Novo Nordisk
  • Nano Precision Medical
  • Nanexa AB
  • Lexaria Bioscience
  • iX Biopharma
  • Intarcia Therapeutics
  • HIKMA PHARMS
  • Eli Lilly
  • Baxter Pharmaceutical
  • Astra Zeneca
  • Amylin Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Dynamics
  1. 2.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
  2. 2.2 GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers
  3. 2.3 GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints
3 GLP-1 Targeted Peptide Weight Loss Drugs Market by Manufacturers
  1. 3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global GLP-1 Targeted Peptide Weight Loss Drugs Manufacturers, Product Type & Application
  7. 3.7 Global GLP-1 Targeted Peptide Weight Loss Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Targeted Peptide Weight Loss Drugs Tier 1, Tier 2, and Tier 3
4 GLP-1 Targeted Peptide Weight Loss Drugs Market by Type
  1. 4.1 GLP-1 Targeted Peptide Weight Loss Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type
  5. 4.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type
  9. 4.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2021-2032)
5 GLP-1 Targeted Peptide Weight Loss Drugs Market by Application
  1. 5.1 GLP-1 Targeted Peptide Weight Loss Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application
  6. 5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application
  10. 5.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2021-2032)
6 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region
  1. 6.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region
  1. 7.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region
  2. 7.1.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032)
  8. 7.2.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032)
  11. 7.3.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chugai Pharmaceutical
  2. 8.1.1 Chugai Pharmaceutical Company Information
  3. 8.1.2 Chugai Pharmaceutical Business Overview
  4. 8.1.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  6. 8.1.5 Chugai Pharmaceutical Recent Developments
  7. 8.2 Benemae Pharmaceutical
  8. 8.2.1 Benemae Pharmaceutical Company Information
  9. 8.2.2 Benemae Pharmaceutical Business Overview
  10. 8.2.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  12. 8.2.5 Benemae Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Jiuyuan Gene Engineering
  20. 8.4.1 Jiuyuan Gene Engineering Company Information
  21. 8.4.2 Jiuyuan Gene Engineering Business Overview
  22. 8.4.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  24. 8.4.5 Jiuyuan Gene Engineering Recent Developments
  25. 8.5 Huadong Medicine
  26. 8.5.1 Huadong Medicine Company Information
  27. 8.5.2 Huadong Medicine Business Overview
  28. 8.5.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  30. 8.5.5 Huadong Medicine Recent Developments
  31. 8.6 Zealand Pharma
  32. 8.6.1 Zealand Pharma Company Information
  33. 8.6.2 Zealand Pharma Business Overview
  34. 8.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  36. 8.6.5 Zealand Pharma Recent Developments
  37. 8.7 The General Hospital Corp
  38. 8.7.1 The General Hospital Corp Company Information
  39. 8.7.2 The General Hospital Corp Business Overview
  40. 8.7.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  42. 8.7.5 The General Hospital Corp Recent Developments
  43. 8.8 Sanofi-Aventis
  44. 8.8.1 Sanofi-Aventis Company Information
  45. 8.8.2 Sanofi-Aventis Business Overview
  46. 8.8.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  48. 8.8.5 Sanofi-Aventis Recent Developments
  49. 8.9 QuiaPEG Pharmaceuticals Ab
  50. 8.9.1 QuiaPEG Pharmaceuticals Ab Company Information
  51. 8.9.2 QuiaPEG Pharmaceuticals Ab Business Overview
  52. 8.9.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  54. 8.9.5 QuiaPEG Pharmaceuticals Ab Recent Developments
  55. 8.10 Orbis Biosciences
  56. 8.10.1 Orbis Biosciences Company Information
  57. 8.10.2 Orbis Biosciences Business Overview
  58. 8.10.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  60. 8.10.5 Orbis Biosciences Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Nano Precision Medical
  68. 8.12.1 Nano Precision Medical Company Information
  69. 8.12.2 Nano Precision Medical Business Overview
  70. 8.12.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  72. 8.12.5 Nano Precision Medical Recent Developments
  73. 8.13 Nanexa AB
  74. 8.13.1 Nanexa AB Company Information
  75. 8.13.2 Nanexa AB Business Overview
  76. 8.13.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  78. 8.13.5 Nanexa AB Recent Developments
  79. 8.14 Lexaria Bioscience
  80. 8.14.1 Lexaria Bioscience Company Information
  81. 8.14.2 Lexaria Bioscience Business Overview
  82. 8.14.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  84. 8.14.5 Lexaria Bioscience Recent Developments
  85. 8.15 iX Biopharma
  86. 8.15.1 iX Biopharma Company Information
  87. 8.15.2 iX Biopharma Business Overview
  88. 8.15.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  90. 8.15.5 iX Biopharma Recent Developments
  91. 8.16 Intarcia Therapeutics
  92. 8.16.1 Intarcia Therapeutics Company Information
  93. 8.16.2 Intarcia Therapeutics Business Overview
  94. 8.16.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  96. 8.16.5 Intarcia Therapeutics Recent Developments
  97. 8.17 HIKMA PHARMS
  98. 8.17.1 HIKMA PHARMS Company Information
  99. 8.17.2 HIKMA PHARMS Business Overview
  100. 8.17.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  102. 8.17.5 HIKMA PHARMS Recent Developments
  103. 8.18 Eli Lilly
  104. 8.18.1 Eli Lilly Company Information
  105. 8.18.2 Eli Lilly Business Overview
  106. 8.18.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  108. 8.18.5 Eli Lilly Recent Developments
  109. 8.19 Baxter Pharmaceutical
  110. 8.19.1 Baxter Pharmaceutical Company Information
  111. 8.19.2 Baxter Pharmaceutical Business Overview
  112. 8.19.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  114. 8.19.5 Baxter Pharmaceutical Recent Developments
  115. 8.20 Astra Zeneca
  116. 8.20.1 Astra Zeneca Company Information
  117. 8.20.2 Astra Zeneca Business Overview
  118. 8.20.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  120. 8.20.5 Astra Zeneca Recent Developments
  121. 8.21 Amylin Pharmaceuticals
  122. 8.21.1 Amylin Pharmaceuticals Company Information
  123. 8.21.2 Amylin Pharmaceuticals Business Overview
  124. 8.21.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  126. 8.21.5 Amylin Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Analysis
  2. 9.1.1 GLP-1 Targeted Peptide Weight Loss Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process
  6. 9.2 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
  9. 9.2.3 GLP-1 Targeted Peptide Weight Loss Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst